HMGA2 promotes epithelial-mesenchymal transition in intrahepatic cholangiocarcinoma via transforming growth factor-β/small mothers against decapentaplegic 2
World Journal of Gastrointestinal Oncology · 2026-11-15 · 18 (11)
DOI: 10.4251/wjgo.121485 ↗Abstract
BACKGROUND Intrahepatic cholangiocarcinoma (ICC) is a highly malignant biliary tract tumor with strong invasiveness, high metastatic potential and poor prognosis. HMGA2 contributes to tumorigenesis and malignant progression in multiple cancers, but its clinical significance, biological functions, and molecular mechanisms in ICC remain unclear. AIM To investigate the clinical significance, biological functions, and molecular mechanisms of HMGA2 in ICC progression. METHODS HMGA2 expression was evaluated by immunohistochemistry in postoperative tumor specimens from 61 patients with ICC and its associations with clinicopathological features and survival were analyzed. ICC cell lines with HMGA2 knockdown or overexpression were established. Cell proliferation, migration, and invasion were assessed using the cell counting kit-8, 5-ethynyl-2’-deoxyuridine incorporation, wound-healing, and Transwell assays. Xenograft experiments evaluated in vivo tumor growth. Western blotting was conducted to detect the expression of HMGA2 , transforming growth factor-β (TGF-β)/small mothers against decapentaplegic 2 (Smad2) pathway-related proteins, and epithelial-mesenchymal transition (EMT)-associated markers. RESULTS HMGA2 positivity was associated with poor overall survival (P = 0.009) and remained an independent prognostic factor [hazard ratio (HR) = 2.271, 95% confidence interval (CI): 1.163-4.437, P = 0.016], along with vascular invasion (HR = 2.040, 95%CI: 1.083-3.844, P = 0.027). Cell counting kit-8 assays showed that HMGA2 overexpression significantly increased ICC cell viability at 24 hours, 48 hours, and 72 hours, whereas HMGA2 knockdown reduced cell viability. 5-ethynyl-2’-deoxyuridine assays further confirmed enhanced proliferation after HMGA2 overexpression (21.20% ± 1.27% vs 17.23% ± 0.95%, P = 0.0073) and reduced proliferation after HMGA2 knockdown (47.77% ± 1.16% vs 55.47% ± 1.33%, P = 0.0006). HMGA2 also promoted migration, invasion, xenograft growth, and TGF-β/Smad2-mediated EMT. CONCLUSION HMGA2 predicts poor prognosis and promotes ICC progression by activating the TGF-β/Smad2/EMT axis, supporting its potential as a biomarker and therapeutic target.
EUVIMED